IL17A and metabolic dysfunction-associated steatotic liver disease: HQGG also acted on various signaling pathways to treat MAFLD, such as the AGE‐RAGE signaling pathway in diabetic complications, lipid and atherosclerosis, non‐alcoholic fatty liver disease, and the IL‐17 signaling pathway.